AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04845555 — intervention group
Intervention type: OTHER
Intervention: Observation of the association between clotting factor level and risk of bleeding whilst physical activity
Description: The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit.
Study NCT04016428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMISM
Description: Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
Study NCT04016428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Six-week online program that provides education on sleep during pregnancy.
Study NCT01585207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vigabatrin
Description: 3 tablets, bid for 8 weeks
Study NCT05325268 — intervention group
Intervention type: PROCEDURE
Intervention: Osteosynthesis
Description: Treatment of fracture with open reduction and osteosynthesis
Study NCT04492696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education
Study NCT03601585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison of dental biofilm removal.
Description: Comparison of the use of 4 methods for dental biofilm removal
Study NCT03601585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of dental biofilm removal.
Description: Comparison of the use of 4 methods for dental biofilm removal
Study NCT01507662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density Result Letter and Bone Health Brochure
Description: Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
Study NCT02034513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02034513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02034513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02034513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02034513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02034513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT03347019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Description: advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
Study NCT03347019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed rehabilitation
Description: Patients were not allowed to start rehabilitation programme first three weeks after surgery.
Study NCT01159873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37251
Description: up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
Study NCT01159873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
Study NCT02386358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
Study NCT02386358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at a dose 5 m/Kg/day until 60 days
Study NCT01731977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based family psychoeducation
Description: Family psychoeducation in a group setting is performed every two weeks for eight weeks.
Study NCT03192813 — intervention group
Intervention type: DEVICE
Intervention: Symetis ACURATE neo™ transfemoral TAVI system
Description: Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
Study NCT03192813 — intervention group
Intervention type: DEVICE
Intervention: Medtronic CoreValve Evolut R TAVI System
Description: Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
Study NCT01020825 — intervention group
Intervention type: DRUG
Intervention: ASCs
Description: Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
Study NCT01020825 — intervention group
Intervention type: DRUG
Intervention: Fibrin glue
Description: After curettage, the fistulous tract was sealed with fibrin glue.
Study NCT01020825 — intervention group
Intervention type: DRUG
Intervention: ASCs
Description: Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
Study NCT03355261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete remission (CR) group
Description: According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
Study NCT03355261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial remission (PR) group
Description: According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
Study NCT03355261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stable disease (SD) group
Description: According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
Study NCT02752854 — intervention group
Intervention type: OTHER
Intervention: pain threshold measurement
Description: pressure algometer
Study NCT03355261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: progressive disease (PD) group
Description: According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
Study NCT05296655 — intervention group
Intervention type: OTHER
Intervention: Reflux Symptom Index Inventory (diagnostic survey)
Description: Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
Study NCT05296655 — intervention group
Intervention type: OTHER
Intervention: Reflux finding score
Description: laryngoscopy with a score RFS
Study NCT04695782 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil beam proton radiotherapy
Description: Doseescalated pencil beam proton Therapy
Study NCT02579551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical excision
Study NCT03497286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-based mentorship
Description: The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
Study NCT03497286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control text messaging
Description: Control participants will receive periodic texts from NurturePA with information about child safety and health.
Study NCT02284854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT02284854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Study NCT03881878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAHP and AHP
Description: (A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)
Study NCT03881878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAHP plus AC and AHP
Description: (A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks
Study NCT00921544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 0.2 ml sucrose 24% given by mouth using a syringe and pacifier
Study NCT00921544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water administered 2 mins prior to eye exam
Study NCT03346746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Diet
Description: This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
Study NCT03346746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Glycaemic Diet
Description: This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
Study NCT02553473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline
Study NCT02553473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study NCT02865824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue thienopyridine
Description: Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
Study NCT02865824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinue thienopyridine
Description: Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
Study NCT03922750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
Study NCT02553473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03706066 — intervention group
Intervention type: DEVICE
Intervention: Acrysof IQ PanOptix IOL
Description: Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
Study NCT03706066 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Per investigator's standard of care
Study NCT02363426 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: INVOcell Culture Device
Description: INVOcell is a vaginal culture device
Study NCT02363426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVF Incubation
Description: IVF Incubator
Study NCT00724035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
Study NCT03412552 — intervention group
Intervention type: DRUG
Intervention: MgSO4
Description: Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
Study NCT01518036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
Study NCT01518036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
Study NCT05299957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PETMRI
Description: PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
Study NCT01140932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
Study NCT01140932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change
Description: High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
Study NCT03021005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Self-testing
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25 without atropine
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes.
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP without atropine
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with atropine
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25 with atropine
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP with atropine
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP plus Xenin-25 without atropine
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Study NCT01951729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP plus Xenin-25 with atropine
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
Study NCT04298112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PSMA PET/CT
Description: Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.
Study NCT04298112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PSMA PET/MR
Description: Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
Study NCT02595879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT02595879 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo LDR brachytherapy
Study NCT02595879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02595879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-PET/CT
Study NCT02595879 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo pelvic EBRT
Study NCT02595879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT
Study NCT00724035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
Study NCT00724035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus nerve block
Description: Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose.
Study NCT00724035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block
Description: Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks.